header_about_team bio_mdemitrack

Mark A. Demitrack, M.D.,

Dr. Demitrack is a psychiatrist with 20 years of experience in the treatment and study of mood disorders and related conditions. He was previously Assistant Vice President of Neuroscience at Wyeth, where he directed post marketing clinical development in support of the Effexor XR brand. Prior to Wyeth, Dr. Demitrack was Medical Director for the New Antidepressant Team at Lilly Research Laboratories. During his tenure at Lilly, he oversaw the registration development and NDA submission of the novel antidepressant, Duloxetine. Prior to his industry experience, he served on the faculty of the University of Michigan Medical Center Department of Psychiatry where he pursued research activities in the neuroendocrine correlates of chronic fatigue syndrome and fibromyalgia, and served as Director of the Michigan Eating Disorders Program. Dr. Demitrack has published extensively on the neuroendocrinology of mood disorders.


Back